• In late June 2026, Alkermes plc reported positive Phase 2 Vibrance-12 results for its oral orexin 2 receptor agonist alixorexton in narcolepsy type 2, while also being added to the Russell 2000 Dynamic Index.
• The combination of clinically meaningful wakefulness and safety data with inclusion in a major benchmark index strengthens Alkermes’ profile in sleep medicine and broadens its visibility with institutional investors.
• Next, we’ll examine how the Vibrance-12 alixorexton data could reshape Alkermes’ orexin franchise narrative and long-term growth balance.

We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Alkermes Investment Narrative Recap

To own Alkermes today, you need to believe that its orexin program, led by alixorexton, can evolve into a meaningful new sleep franchise alongside Vivitrol, Aristada and Lybalvi. The latest Vibrance-12 Phase 2 data in narcolepsy type 2 and inclusion in the Russell 2000 Dynamic Index both reinforce the importance of the Brilliance Phase 3 program as the key near term catalyst, while late stage trial and regulatory outcomes remain the biggest swing risk.

Among recent announcements, the launch of the global Phase 3 Brilliance program for alixorexton ties most directly to the Vibrance-12 update. The Phase 2 results in narcolepsy type 2 strengthen the clinical rationale for this program, but they do not remove the execution and outcome risks around Phase 3 trial performance, regulatory expectations on endpoints like wakefulness and potential safety scrutiny across the orexin class.

Yet against this clinical momentum, investors still need to watch the unresolved regulatory risk around orexin safety and label restrictions that could...

Alkermes' narrative projects $2.1 billion revenue and $264.8 million earnings by 2029. This requires 11.1% yearly revenue growth and about a $112 million earnings increase from $152.7 million today.

Uncover how Alkermes' forecasts yield a $47.69 fair value, a 13% downside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were expecting Alkermes revenue to fall to about US$1.3 billion and earnings to about US$183.7 million, highlighting how much more cautious they were about orexin competition and pricing pressure, even before this latest Vibrance update, and reminding you that views on the same data can differ widely.

Explore 5 other fair value estimates on Alkermes - why the stock might be worth as much as 86% more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Alkermes research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Alkermes research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Alkermes' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Our top stock finds are flying under the radar-for now. Get in early:

• The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
• Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.